Inhibitory effects of CP on the growth of human gastric adenocarcinoma BGC-823 tumours in nude mice

Objective To investigate the potential antitumour effects of [2-(6-amino-purine-9-yl)-1-hydroxy-phosphine acyl ethyl] phosphonic acid (CP) against gastric adenocarcinoma. Methods Human BGC-823 xenotransplants were established in nude mice. Animals were randomly divided into control and CP groups, which were administered NaHCO3 vehicle alone or CP dissolved in NaHCO3 (200 µg/kg body weight) daily, respectively. Tumour volume was measured weekly for 6 weeks. Resected tumours were assayed for proliferative activity with anti-Ki-67 or anti-proliferating cell nuclear antigen (PCNA) antibodies. Cell apoptosis was examined using terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) assays and with caspase-3 immunostaining. Proteins were measured by Western blotting. Results There was a significant reduction in tumour volume and a reduced percentage of Ki-67-positive or PCNA-positive cells in the CP group compared with the control group. The percentage of TUNEL-positive or caspase 3-positive cells significantly increased following CP treatment compared with the control group. Tumours from the CP group had higher levels of phosphorylated-extracellular signal-regulated kinase (p-ERK) and phosphorylated-AKT (p-AKT) compared with control tumours. Conclusion CP treatment inhibited tumour growth and induced tumour cell apoptosis in a nude mouse model of BGC-823 gastric adenocarcinoma. Activation of the AKT and ERK signalling pathways may mediate this antitumour activity.

[1]  O. Bouché,et al.  Recent insights in the therapeutic management of patients with gastric cancer. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  S. Davis,et al.  Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. , 2016, Bone.

[3]  Š. Polák,et al.  Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. , 2016, Acta histochemica.

[4]  Chuying Huang,et al.  Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations. , 2016, Oncology reports.

[5]  H. Chun,et al.  Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. , 2016, World journal of gastroenterology.

[6]  J. Araya,et al.  The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines , 2016, Pathology & Oncology Research.

[7]  Yi Yang,et al.  Functional role of autophagy in gastric cancer , 2016, Oncotarget.

[8]  A. Branch,et al.  Bisphosphonates as potential adjuvants for patients with cancers of the digestive system. , 2016, World journal of gastroenterology.

[9]  M. Gnant,et al.  Adjuvant Bisphosphonates and Breast Cancer Survival. , 2016, Annual review of medicine.

[10]  G. Sethi,et al.  Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine? , 2015, World journal of gastroenterology.

[11]  Mei-hua Yang,et al.  Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. , 2015, World journal of gastroenterology.

[12]  Hyeon-soo Park,et al.  Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells. , 2015, International journal of oncology.

[13]  A. Zetterberg,et al.  A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer. , 2015, Annals of diagnostic pathology.

[14]  F. Roviello,et al.  Multimodal treatment of gastric cancer in the west: Where are we going? , 2015, World journal of gastroenterology.

[15]  Xuan Yuan,et al.  Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways , 2015, Scientific Reports.

[16]  Xiaojing Yan,et al.  A meta-analysis of the antitumor effect and safety of bisphosphonates in the treatment of multiple myeloma. , 2015, International journal of clinical and experimental medicine.

[17]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[18]  T. Yuen,et al.  Bisphosphonates inactivate human EGFRs to exert antitumor actions , 2014, Proceedings of the National Academy of Sciences.

[19]  Y. Lei,et al.  Mitogen-activated protein kinase signal transduction in solid tumors. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[20]  X. Zhong,et al.  Zoledronic acid exerts antitumor effects in NB4 acute promyelocytic leukemia cells by inducing apoptosis and S phase arrest. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  M. Shintani,et al.  Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas. , 2014, International journal of clinical and experimental pathology.

[22]  Yong Li,et al.  A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway , 2013, Acta Pharmacologica Sinica.

[23]  L. Boise,et al.  Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis , 2013, BMC Cell Biology.

[24]  M. Gnant,et al.  Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. , 2012, Cancer treatment reviews.

[25]  Hiroshi Kobayashi,et al.  Zoledronic Acid Produces Antitumor Effects on Mesothelioma Through Apoptosis and S-Phase Arrest in p53-Independent and Ras prenylation-Independent Manners , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  R. Eastell,et al.  Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study , 2012, Osteoporosis International.

[27]  S. Culine,et al.  Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone. , 2012, Anti-cancer drugs.

[28]  M. Malafa,et al.  Targeting AKT protein kinase in gastric cancer. , 2011, Anticancer research.

[29]  Jung lim Kim,et al.  Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression. , 2011, Experimental cell research.

[30]  B. Abrahamsen,et al.  Safety of bisphosphonates. , 2011, Bone.

[31]  J. Chang,et al.  Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression , 2011, Anti-cancer drugs.

[32]  P. Clézardin.  Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. , 2011, Bone.

[33]  Y Zhang,et al.  Gastric cancer exosomes promote tumour cell proliferation through PI3K/Akt and MAPK/ERK activation. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[34]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.